Breaking: Corillian Corp (NASDAQ:CORI) Stock Price Down as Sentiment Crashes

November 18, 2016 - By Darrin Black   ·   0 Comments

Breaking: Corillian Corp (NASDAQ:CORI) Stock Price Down as Sentiment  Crashes

Sentiment for Corillian Corp (NASDAQ:CORI)

Corillian Corp (NASDAQ:CORI) institutional sentiment decreased to 0.69 in Q2 2016. Its down -0.04, from 0.73 in 2016Q1. The ratio turned negative, as 19 institutional investors increased or opened new stock positions, while 26 reduced and sold holdings in Corillian Corp. The institutional investors in our partner’s database now own: 18.39 million shares, down from 18.94 million shares in 2016Q1. Also, the number of institutional investors holding Corillian Corp in their top 10 stock positions was flat from 1 to 1 for the same number . Sold All: 12 Reduced: 14 Increased: 11 New Position: 8.

Corium International, Inc. is a biopharmaceutical company. The company has a market cap of $101.35 million. The Firm is engaged in the development, manufacture and commercialization of specialty pharmaceutical products that focuses on transdermal and transmucosal delivery systems. It currently has negative earnings. The Company’s development platforms enable transdermal delivery of large molecules, or biologics, including vaccines, peptides and proteins, as well as small molecules.

About 3,473 shares traded hands. Corium International Inc (NASDAQ:CORI) has risen 21.63% since April 18, 2016 and is uptrending. It has outperformed by 17.20% the S&P500.

According to Zacks Investment Research, “Corium International, Inc. is a commercial-stage biopharmaceutical company. It is focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage advanced technologies in transdermal and transmucosal delivery systems. Corium has developed six marketed products in the prescription drug and consumer markets: Clonidine Transdermal Delivery System for hypertension, Fentanyl TDS for chronic pain and four Crest Advanced Seal Whitestrips products. The company has two proprietary transdermal technology platforms with applications in multiple drug categories and indications: Corplex(TM) and MicroCor(R). Corium International, Inc. is headquartered in Menlo Park, California.”

Essex Woodlands Health Ventures Inc. holds 8.18% of its portfolio in Corium International Inc for 9.35 million shares. Opaleye Management Inc. owns 125,000 shares or 1.4% of their US portfolio. Moreover, Rtw Investments Llc has 1.01% invested in the company for 852,961 shares. The New York-based Broadfin Capital Llc has invested 0.65% in the stock. Wall Street Associates, a California-based fund reported 265,700 shares.#img1#

Corium International Inc (NASDAQ:CORI) Ratings Coverage

Ratings analysis reveals 80% of Corium International’s analysts are positive. Out of 5 Wall Street analysts rating Corium International, 4 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $11 while the high is $20. The stock’s average target of $13.40 is 157.69% above today’s ($5.2) share price. CORI was included in 9 notes of analysts from August 25, 2015. The rating was downgraded by WBB Securities on Monday, August 31 to “Hold”. Needham maintained it with “Buy” rating and $16 target price in Monday, November 16 report. Needham maintained Corium International Inc (NASDAQ:CORI) rating on Tuesday, February 9. Needham has “Buy” rating and $15 price target. Zacks downgraded Corium International Inc (NASDAQ:CORI) on Tuesday, August 25 to “Buy” rating. As per Wednesday, September 2, the company rating was upgraded by Zacks.

CORI Company Profile

Corium International, Inc., incorporated on February 28, 2002, is a biopharmaceutical company. The Firm is engaged in the development, manufacture and commercialization of specialty pharmaceutical products that focuses on transdermal and transmucosal delivery systems. The Company’s development platforms enable transdermal delivery of large molecules, or biologics, including vaccines, peptides and proteins, as well as small molecules that are difficult to deliver in a transdermal dosage form. The Company’s Corplex and MicroCor platforms address some of the primary shortcomings of traditional transdermal drug delivery.

Another recent and important Corium International Inc (NASDAQ:CORI) news was published by Quotes.Wsj.com which published an article titled: “News Corium International Inc.CORI” on April 16, 2011.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Darrin Black


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>